CD19 and systemic sclerosis: Based on the findings of these studies, CD19 CAR-T therapy in SSc is demonstrated as a rapid inducer of B cell aplasia, while significantly regressing fibrosis (both cutaneous and pulmonary), resulting in durable clinical remission with an acceptable safety profile.